Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Biomaterials. 2017 Nov 20;156:194–203. doi: 10.1016/j.biomaterials.2017.11.022

Figure 4. ELISpot analysis of splenocytes from immunization with MAGE-A3 formulations.

Figure 4

A) Vaccine components per dose of different formulation groups (a–e). B) Summary of averaged ELISpot data, which evaluated antigen-specific IFN-γ secretion. HLA-A2 mice were immunized with different formulations (a–e), and splenocytes were pulsed ex vivo in the presence of relevant peptide (MAGE) or irrelevant peptide (SIINFEKL) and analyzed for specific IFN-γ secretion. Higher MAGE-A3 epitope-specific IFN-γ secretion was observed for the group that received CpG-MAGE-E2. Data is presented as average ± S.E.M. of 3 independent experiments (n ≥ 3). Statistical significance was determined by two-way ANOVA followed by a Tukey's test (**p < 0.01; ***p < 0.001).